市場調查報告書
商品編碼
1291598
癌症/腫瘤分析市場:2023-2028年全球行業趨勢、佔有率、規模、成長、機會和預測Cancer/Tumor Profiling Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年,全球癌症/腫瘤分析市場規模達到104億美元。展望未來,IMARC Group預計到2028年市場規模將達到184億美元,在2023-2028年期間表現出9.8%的成長率(CAGR)。
癌症/腫瘤特徵分析,也被稱為生物標記測試,是指用於識別腫瘤組織樣本中特定蛋白質、基因或基因突變(變化)和其他生物標記的實驗室測試或程序。它協助腫瘤學家確定病人的腫瘤路徑是否與現有的靶向治療相匹配。它還有助於常規診斷、治療決策,以及根據個人疾病的嚴重程度和基因組的積累為其製定個性化的治療計劃和療法。癌症/腫瘤特徵分析還在個性化醫療、研究、生物標記的發現以及篩查和診斷技術的發展中得到了廣泛的應用。
癌症/腫瘤特徵分析被廣泛用於腫瘤學研究和藥物設計、發現和開發過程中的生物標記的發現。因此,全球範圍內癌症的廣泛流行是推動市場成長的主要因素。除此之外,對診斷和腫瘤剖析的生物標記的日益關注,以及大眾對個性化醫療的偏好的轉變,都增加了產品的需求。此外,政府對癌症研究的資助和支持顯著增加,以開發先進技術,減少檢測和識別腫瘤所需的時間。與此同時,分子生物學技術的最新進展,如下一代測序(NGS),正在加速癌症/腫瘤剖析的採用。此外,製藥和生物技術公司為推出新型療法和新的藥物設計技術而在研究和開發(R&D)活動中的投資不斷增加,正在推動市場成長。其他因素,包括不斷增加的臨床試驗,擴大採用免疫測定技術,有利的報銷政策,不斷改善的醫療基礎設施,以及技術進步,也為市場創造了積極的前景。
The global cancer/tumor profiling market size reached US$ 10.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 18.4 Billion by 2028, exhibiting a growth rate (CAGR) of 9.8% during 2023-2028.
Cancer/tumor profiling, also known as biomarker testing, refers to a laboratory test or procedure used to identify specific proteins, genes or gene mutations (changes) and other biomarkers in a tumor tissue sample. It assists oncologists in determining if the pathways of a patient's tumor match up with the available targeted therapies. It also aids in routine diagnostics, therapeutic decision-making, and developing personalized treatment plans and therapies for individuals based on the severity of their ailment and genomic build-up. Cancer/tumor profiling also finds extensive applications in personalized medicine, research, the discovery of biomarkers, and the development of screening and diagnostic techniques.
Cancer/tumor profiling is widely used in oncology research and discovery of biomarkers during the process of drug design, discovery and development. As a result, the widespread prevalence of cancer across the globe represents the primary factor driving the market growth. Besides this, the growing focus on biomarkers for diagnosis and tumor profiling and the shifting preferences toward personalized medicine among the masses are augmenting the product demand. Additionally, there has been a significant rise in government funding and support for cancer research for the development of advanced techniques to reduce the time taken for the detection and identification of tumors. Along with this, the recent advancements in molecular biology techniques, such as next-generation sequencing (NGS), are accelerating the adoption of cancer/tumor profiling. Furthermore, the increasing investments by pharmaceutical and biotechnology companies in research and development (R&D) activities for the launch of novel therapies and new drug designing techniques are propelling the market growth. Other factors, including the rising number of clinical trials, growing adoption of immunoassay techniques, favorable reimbursement policies, improving healthcare infrastructure, and technological advancements, are also creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer/tumor profiling market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on cancer type, technology, technique and application.
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma Cancer
Others
Next-Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Immunohistochemistry (IHC)
In-Situ Hybridization (ISH)
Microarray
Others
Genomics
Proteomics
Epigenetics
Metabolomics
Personalized Medicine
Diagnostics
Biomarker Discovery
Prognostics
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Hologic Inc., HTG Molecular Diagnostics Inc., Illumina Inc., Laboratory Corporation of America Holdings, NeoGenomics Laboratories, Qiagen N.V., Siemens AG and Sysmex Corporation.
Key Questions Answered in This Report
1. What was the size of the global cancer/tumor profiling market in 2022?
2. What is the expected growth rate of the global cancer/tumor profiling market during 2023-2028?
3. What has been the impact of COVID-19 on the global cancer/tumor profiling market?
4. What are the key factors driving the global cancer/tumor profiling market?
5. What is the breakup of the global cancer/tumor profiling market based on the cancer type?
6. What is the breakup of the global cancer/tumor profiling market based on the technique?
7. What are the key regions in the global cancer/tumor profiling market?
8. Who are the key players/companies in the global cancer/tumor profiling market?